Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases

Quan Dong Nguyen, Sandro De Falco, Francine Behar-Cohen, Wai Ching Lam, Xuri Li, Nadine Reichhart, Federico Ricci, Jennifer Pluim, William W. Li

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

The role of vascular endothelial growth factor (VEGF), including in retinal vascular diseases, has been well studied, and pharmacological blockade of VEGF is the gold standard of treatment for neovascular age-related macular degeneration, retinal vein occlusion and diabetic macular oedema. Placental growth factor (PGF, previously known as PlGF), a homologue of VEGF, is a multifunctional peptide associated with angiogenesis-dependent pathologies in the eye and non-ocular conditions. Animal studies using genetic modification and pharmacological treatment have demonstrated a mechanistic role for PGF in pathological angiogenesis. Inhibition decreases neovascularization and microvascular abnormalities across different models, including oxygen-induced retinopathy, laser-induced choroidal neovascularization and in diabetic mice exhibiting retinopathies. High levels of PGF have been found in the vitreous of patients with diabetic retinopathy. Despite these strong animal data, the exact role of PGF in pathological angiogenesis in retinal vascular diseases remains to be defined, and the benefits of PGF-specific inhibition in humans with retinal neovascular diseases and macular oedema remain controversial. Comparative effectiveness research studies in patients with diabetic retinal disease have shown that treatment that inhibits both VEGF and PGF may provide superior outcomes in certain patients compared with treatment that inhibits only VEGF. This review summarizes current knowledge of PGF, including its relationship to VEGF and its role in pathological angiogenesis in retinal diseases, and identifies some key unanswered questions about PGF that can serve as a pathway for future basic, translational and clinical research.

Original languageEnglish (US)
Pages (from-to)e1-e9
JournalActa Ophthalmologica
Volume96
Issue number1
DOIs
StatePublished - Feb 1 2018

Fingerprint

Eye Diseases
Prostaglandins F
Diabetic Retinopathy
Intercellular Signaling Peptides and Proteins
Retinal Diseases
Vascular Endothelial Growth Factor A
Pathologic Neovascularization
Retinal Vessels
Macular Edema
Vascular Diseases
Comparative Effectiveness Research
Pharmacology
Retinal Vein Occlusion
Choroidal Neovascularization
Translational Medical Research
Macular Degeneration
Therapeutics
Lasers
Pathology
Oxygen

Keywords

  • angiogenesis
  • diabetic retinopathy
  • neovascularization
  • placental growth factor
  • retina
  • vascular endothelial growth factor

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Nguyen, Q. D., De Falco, S., Behar-Cohen, F., Lam, W. C., Li, X., Reichhart, N., ... Li, W. W. (2018). Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases. Acta Ophthalmologica, 96(1), e1-e9. https://doi.org/10.1111/aos.13325

Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases. / Nguyen, Quan Dong; De Falco, Sandro; Behar-Cohen, Francine; Lam, Wai Ching; Li, Xuri; Reichhart, Nadine; Ricci, Federico; Pluim, Jennifer; Li, William W.

In: Acta Ophthalmologica, Vol. 96, No. 1, 01.02.2018, p. e1-e9.

Research output: Contribution to journalReview article

Nguyen, QD, De Falco, S, Behar-Cohen, F, Lam, WC, Li, X, Reichhart, N, Ricci, F, Pluim, J & Li, WW 2018, 'Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases', Acta Ophthalmologica, vol. 96, no. 1, pp. e1-e9. https://doi.org/10.1111/aos.13325
Nguyen, Quan Dong ; De Falco, Sandro ; Behar-Cohen, Francine ; Lam, Wai Ching ; Li, Xuri ; Reichhart, Nadine ; Ricci, Federico ; Pluim, Jennifer ; Li, William W. / Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases. In: Acta Ophthalmologica. 2018 ; Vol. 96, No. 1. pp. e1-e9.
@article{02560963580d437aaa3c80100cb6932a,
title = "Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases",
abstract = "The role of vascular endothelial growth factor (VEGF), including in retinal vascular diseases, has been well studied, and pharmacological blockade of VEGF is the gold standard of treatment for neovascular age-related macular degeneration, retinal vein occlusion and diabetic macular oedema. Placental growth factor (PGF, previously known as PlGF), a homologue of VEGF, is a multifunctional peptide associated with angiogenesis-dependent pathologies in the eye and non-ocular conditions. Animal studies using genetic modification and pharmacological treatment have demonstrated a mechanistic role for PGF in pathological angiogenesis. Inhibition decreases neovascularization and microvascular abnormalities across different models, including oxygen-induced retinopathy, laser-induced choroidal neovascularization and in diabetic mice exhibiting retinopathies. High levels of PGF have been found in the vitreous of patients with diabetic retinopathy. Despite these strong animal data, the exact role of PGF in pathological angiogenesis in retinal vascular diseases remains to be defined, and the benefits of PGF-specific inhibition in humans with retinal neovascular diseases and macular oedema remain controversial. Comparative effectiveness research studies in patients with diabetic retinal disease have shown that treatment that inhibits both VEGF and PGF may provide superior outcomes in certain patients compared with treatment that inhibits only VEGF. This review summarizes current knowledge of PGF, including its relationship to VEGF and its role in pathological angiogenesis in retinal diseases, and identifies some key unanswered questions about PGF that can serve as a pathway for future basic, translational and clinical research.",
keywords = "angiogenesis, diabetic retinopathy, neovascularization, placental growth factor, retina, vascular endothelial growth factor",
author = "Nguyen, {Quan Dong} and {De Falco}, Sandro and Francine Behar-Cohen and Lam, {Wai Ching} and Xuri Li and Nadine Reichhart and Federico Ricci and Jennifer Pluim and Li, {William W.}",
year = "2018",
month = "2",
day = "1",
doi = "10.1111/aos.13325",
language = "English (US)",
volume = "96",
pages = "e1--e9",
journal = "Acta Ophthalmologica",
issn = "1755-375X",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases

AU - Nguyen, Quan Dong

AU - De Falco, Sandro

AU - Behar-Cohen, Francine

AU - Lam, Wai Ching

AU - Li, Xuri

AU - Reichhart, Nadine

AU - Ricci, Federico

AU - Pluim, Jennifer

AU - Li, William W.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - The role of vascular endothelial growth factor (VEGF), including in retinal vascular diseases, has been well studied, and pharmacological blockade of VEGF is the gold standard of treatment for neovascular age-related macular degeneration, retinal vein occlusion and diabetic macular oedema. Placental growth factor (PGF, previously known as PlGF), a homologue of VEGF, is a multifunctional peptide associated with angiogenesis-dependent pathologies in the eye and non-ocular conditions. Animal studies using genetic modification and pharmacological treatment have demonstrated a mechanistic role for PGF in pathological angiogenesis. Inhibition decreases neovascularization and microvascular abnormalities across different models, including oxygen-induced retinopathy, laser-induced choroidal neovascularization and in diabetic mice exhibiting retinopathies. High levels of PGF have been found in the vitreous of patients with diabetic retinopathy. Despite these strong animal data, the exact role of PGF in pathological angiogenesis in retinal vascular diseases remains to be defined, and the benefits of PGF-specific inhibition in humans with retinal neovascular diseases and macular oedema remain controversial. Comparative effectiveness research studies in patients with diabetic retinal disease have shown that treatment that inhibits both VEGF and PGF may provide superior outcomes in certain patients compared with treatment that inhibits only VEGF. This review summarizes current knowledge of PGF, including its relationship to VEGF and its role in pathological angiogenesis in retinal diseases, and identifies some key unanswered questions about PGF that can serve as a pathway for future basic, translational and clinical research.

AB - The role of vascular endothelial growth factor (VEGF), including in retinal vascular diseases, has been well studied, and pharmacological blockade of VEGF is the gold standard of treatment for neovascular age-related macular degeneration, retinal vein occlusion and diabetic macular oedema. Placental growth factor (PGF, previously known as PlGF), a homologue of VEGF, is a multifunctional peptide associated with angiogenesis-dependent pathologies in the eye and non-ocular conditions. Animal studies using genetic modification and pharmacological treatment have demonstrated a mechanistic role for PGF in pathological angiogenesis. Inhibition decreases neovascularization and microvascular abnormalities across different models, including oxygen-induced retinopathy, laser-induced choroidal neovascularization and in diabetic mice exhibiting retinopathies. High levels of PGF have been found in the vitreous of patients with diabetic retinopathy. Despite these strong animal data, the exact role of PGF in pathological angiogenesis in retinal vascular diseases remains to be defined, and the benefits of PGF-specific inhibition in humans with retinal neovascular diseases and macular oedema remain controversial. Comparative effectiveness research studies in patients with diabetic retinal disease have shown that treatment that inhibits both VEGF and PGF may provide superior outcomes in certain patients compared with treatment that inhibits only VEGF. This review summarizes current knowledge of PGF, including its relationship to VEGF and its role in pathological angiogenesis in retinal diseases, and identifies some key unanswered questions about PGF that can serve as a pathway for future basic, translational and clinical research.

KW - angiogenesis

KW - diabetic retinopathy

KW - neovascularization

KW - placental growth factor

KW - retina

KW - vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=85006078289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006078289&partnerID=8YFLogxK

U2 - 10.1111/aos.13325

DO - 10.1111/aos.13325

M3 - Review article

C2 - 27874278

AN - SCOPUS:85006078289

VL - 96

SP - e1-e9

JO - Acta Ophthalmologica

JF - Acta Ophthalmologica

SN - 1755-375X

IS - 1

ER -